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Panax ginseng is a well-known economic medical plant that is widely used in Chinese traditional
medicine. This species contains a unique class of natural productsdginsenosides. Recent clinical and
experimental studies have presented numerous lines of evidence on the promising role of ginsenosides
on different diseases including neurodegenerative diseases, cardiovascular diseases, and certain types of
cancer. Nowadays, most of the attention has focused on ginsenoside Rd as a neuroprotective agent to
attenuate ischemic stroke damages. Some of the evidence showed that ginsenoside Rd ameliorates
ischemic stroke-induced damages through the suppression of oxidative stress and inflammation. Gin-
senoside Rd can prolong neural cells’ survival through the upregulation of the endogenous antioxidant
system, phosphoinositide-3-kinase/AKT and extracellular signal-regulated protein kinase 1/2 pathways,
preservation of mitochondrial membrane potential, suppression of the nuclear factor-kappa B, transient
receptor potential melastatin, acid sensing ion channels 1a, poly(ADP-ribose) polymerase-1, protein
tyrosine kinase activation, as well as reduction of cytochrome c-releasing and apoptosis-inducing factor.
In the current work, we review the available reports on the promising role of ginsenoside Rd on ischemic
stroke. We also discuss its chemistry, source, and the molecular mechanism underlying this effect.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Stroke, which statistically ranks as the third leading cause of
death and as the most important cause of permanent disability
worldwide, is classified into ischemic and hemorrhagic stroke [1e
3]. Nearly 80% of stroke patients suffer from ischemic stroke,
which results from artery and/or vascular occlusion inducing a
transient or permanent reduction in blood supply to the different
regions of the brain [4,5]. Old age, smoking, and concomitant dis-
eases such as obesity, diabetes, and hypertension are risk factors of
stroke [6e10]. Statistical data also show that the occurrence of
stroke events is asymmetrical in different sexes and ethnicities
[11,12].
In addition, stroke is associated with several complications
including depression, insomnia, or cognitive impairment, which
have detrimental effects on therapeutic outcomes, increasingearch Center, Baqiyatallah Univers
vi).
ht  2015, The Korean Society of G
c-nd/4.0/).medical costs and mortality rate [13e16]. Experimental and clinical
evidence also showed that depending on the ischemic/reperfusion
duration, infarct volume and site, patient age, and the presence of
concomitant diseases, the stroke-induced complications and mor-
tality rate are different [14,17e20]. Oxidative stress and systemic
inflammation appear to have a key role in the pathophysiology of
ischemic stroke and stroke-induced complications [21e23]. A
growing body of evidence obtained from epidemiological studies
shows that diets containing large amounts of vegetables and fruits
decrease the risk of ischemic stroke [24e26]. This reality is sup-
ported by extensive experimental studies on isolated phytochem-
icals [27e30]. A plethora of evidence also shows the antioxidant
and anti-inflammatory effects of these phytochemicals [31e34],
which seem to be promising compounds against ischemic stroke
[35,36]. During the past decades, much attention has been paid to
health promotion related to the activity of phytochemicals and aity of Medical Sciences, P.O. Box 19395-5487, Tehran, Iran. Tel.: þ98 21 88617712;
inseng, Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
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Fig. 1. Structure of ginsenoside Rd and related ginsenosides.
J Ginseng Res 2015;39:299e303300great revolution occurred in the use of medical plant-derived
phytochemicals as effective strategy for the treatment of different
diseases [37e45].
Panax ginseng Meyer (Korean red ginseng) is a well-known
medicinal plant from eastern Asian countries, especially Korea ,
China , and Japan [46,47], and its root has been used since ancient
times for the treatment of numerous diseases and increasing
physical strength [48,49]. The word Panax originates from the word
“panacea,” which means “cure all diseases,” and refers to a tradi-
tional belief about its promising effects on longevity and health
promotion [46]. The therapeutic role of Panax ginseng on several
diseases such as cancer and cardiovascular diseases, has been re-
ported by recent experimental and clinical studies on ginseng and/
or its bioactive constituents [50e54]. The first attempts to isolate
the active constituents of ginseng began many years ago, leading to
the isolation of ginsenosides in 1963 [55]. To date, > 40 different
ginsenosides have been found [56]. Extensive studies evaluated the
different pharmacological activities of ginsenosides, such as their
ability to suppress inflammation and oxidative stress as well as
their vasorelaxation effect [57e61]. Many lines of evidence also
showed the promising effects of ginseng and its purified ginseno-
side constituents on cardiovascular disease and its risk factors
[54,62e68]. The promising role of ginsenosides Rd on ischemic
stroke is widely publicized [69e71]. The aim of this paper is to
review the available reports on the therapeutic role of ginsenosides
Rd on ischemic stroke. We also discuss the molecular mechanism
underlying this effect, as well as the chemistry and safety of gin-
senoside Rd.
2. Source and chemistry
Ginseng has been used for thousands of years in folkmedicine in
Eastern Asia. The most popular ginseng comes from the root of
P. ginseng Meyer, a slow-growing perennial plant belonging to the
family Araliaceae. The plant is native to China and Korea but is now
widely cultivated in other countries including Japan, Russia, United
States, and Canada. The vast array of medicinal uses of P. ginseng
includes its use as a remedy against aging, diabetes, sleep disorders,
and sexual dysfunction [72,73]. In addition to ginseng from
P. ginsengdcommonly known as Asian, Chinese, or Korean gin-
sengdAmerican ginseng (from Panax quinquefolius) is also
available.
The active principles responsible for the pharmacological ac-
tivities of ginseng are a group of unique triterpene glycosides or
saponins called ginsenosides. The chemical structure of one of the
best-known active ingredients, ginseng Rd, along with some
related ginsenosides, is shown in Fig. 1. These compounds are based
on the dammarane triterpene skeleton that is hydroxylated at three
positions (C-3, C-12, and C-20 positions) to produce proto-
panaxadiol (Fig.1). Based on the variability in the type of sugars and
the degree of glycosylation at the C-3 and C-20 positions, several
ginsenosides of protopanaxadiol skeleton have been identified
from ginseng (Fig. 1). Remarkably, hydroxylation at the C-6 position
of protopanaxadiol is also possible, leading to further structural
diversities via glycosylation.
Today, the quality control of ginseng is a difficult task owing to
the diversity of plant sources, which include P. ginseng, Panax
notoginseng, P. quinquefolius, and Panax japonicas, and the vari-
ability in the composition (> 150 ginsenosides are known in the
genus, and > 35 are found in the roots) [56,62,74] based on plant
age, harvesting conditions, and growing media such as soil, tem-
perature, light intensity, and water content [75e79]. One alterna-
tive approach is to use the most active ginsenoside, such as
ginsenoside Rd; however, the low yield (as low as 0.4%) coupled
with the difficulty and high cost of isolating the compound from thecomplex mixture pose a great barrier. Fortunately, the major
component of ginsenosides is Rb1, which differs from Rd in that it
has two glucose units at C-20 position instead of only one (Fig.1). To
date, a number of enzyme and/or microbial-based biotransforma-
tion [80e88] methodologies have been proposed to obtain ginse-
noside Rd. The exploitation of ginsenosides from plant cell cultures
is also an active topic of current research [89,90]. Further de-
velopments in these research areas are therefore likely to make the
concept of using ginsenoside Rd as a single chemical entity very
feasible.3. Ginsenoside Rd and ischemic stroke
The promising effect of pre- and/or posttreatment of ginseno-
side Rd on ischemic stroke-induced neural damages has been
studied in different experimental models including transient mid-
dle cerebral artery occlusion (tMCAO) in rat and mice [91e93],
oxygen glucose deprivation-induced damages to hippocampal
neuron [70], or glutamate-induced damages in rat cortical neurons
[94]. Evidence obtained from in vitro and in vivo studies shows that
ginsenoside Rd treatment prior to and/or following an ischemic
stroke can reduce infarct volume [69,91,92], increase neuronal
survival (Fig. 2) [70,94e96], and enhance cognitive and neurolog-
ical functions [91,92,97]. Ginsenoside Rd administration to a Spra-
gueeDawley rat has been shown to downregulate ischemic stroke-
Fig. 2. Molecular mechanisms underlying the promising effects of ginsenoside Rd on ischemic stroke. COX-2, cyclooxygenase-2; ERK 1/2 , extracellular signal-regulated protein
kinases 1 and 2; GLT-1, glial glutamate transporter-1; GSK-3b, glycogen synthase kinase-3b; iNOS, inducible nitric oxide synthase; MMP, mitochondrial membrane potential; NF-kB,
nuclear factor-kappa B; PARP-1, poly(ADP-ribose) polymerase 1; PI3K/AKT, phosphatidylinositol 3-kinase/AKT; ROS, reactive oxygen species.
S.F. Nabavi et al / Ginsenoside Rd and stroke 301induced tau protein phosphorylation at Ser199/202 and PHF-1 sites
through the downregulation of glycogen synthase kinase-3b and to
enhance ischemia-induced cognitive impairment [97]. Ginsenoside
Rd administration has also been shown to upregulate the protein
kinase B/AKT pathway and, from this, suppress glycogen synthase
kinase-3b activity [97]. Ginsenoside Rd administration after tMCAO
upregulates glial glutamate transporter-1 (GLT-1) expression and
promotes glutamate clearance in rats [95]. Similarly, exposing
ginsenoside Rd to astrocyte cells increases glutamate uptake after
oxygen-glucose deprivation. It is also reported that phosphorylated
protein kinase B and phospho-extracellular signal-regulated pro-
tein kinase (ERK) 1/2 pathways have a crucial role in the promising
effect of ginsenoside Rd on glutamate uptake and GLT-1 expression
[95]. Ginsenoside Rd is also a selective and competitive Ca2þ re-
ceptor antagonist and, therefore, can suppress calcium influx after
cytotoxic injuries [93]. A previous study showed that pretreatment
with ginsenoside Rd (10mg/kg) increases acid sensing ion channels
2a and suppresses transient receptor potential melastatin, and acid
sensing ion channels 1a expression in tMCAO-induced ischemic
rats and, through this effect, prolongs neuronal survival [93]. An
in vitro study on rat cortical neurons reported that ginsenoside Rd
administration dose-dependently suppresses glutamate-induced
DNA laddering and apoptosis through the suppression of
glutamate-induced caspase-3 activation and Ca2þ entry [94].
Another study showed that pretreatment with ginsenoside Rd
(10 mg/kg) inhibits poly(ADP-ribose) polymerase-1 and conse-
quently downregulates apoptosis-inducing factor translocation and
nuclear factor-kappa B p65 subunit nuclear accumulation in Daw-
ley rats suffering from right middle cerebral artery occlusion [96].
This finding supported the concept that both the antiapoptotic and
anti-inflammatory effects of ginsenoside Rd may be responsible for
its promising effects on ischemic stroke [96].
Another study on 16- to 18-month-old mice suffering from
tMCAO-induced ischemic stroke shows that pretreatment with
ginsenoside Rd (10e50 mg/kg) significantly decreases cortical
and striatal infarct size and oxidative stress (DNA damage, pro-
tein carbonyl formation, and lipid peroxidation) [91]. Ginsenoside
Rd also upregulates the endogenous antioxidant system, sustains
the mitochondrial respiratory chain complex and aconitase ac-
tivities, downregulates mitochondrial hydrogen peroxide leakage,and stabilizes mitochondrial membrane potential [91]. In addi-
tion to these effects, another similar report also showed that
ginsenoside Rd administration (50 mg/kg) to rats prior to tMCAO
significantly decreases the infarcted area (52.8%), and decreases
the lactate/pyruvate ratio, the reactive oxygen species produc-
tion, cytochrome releasing, and apoptosis-inducing factor [92].
Similarly, an in vitro study showed that exposure to ginsenoside
Rd can also protect mitochondria against calcium-induced dam-
ages through downregulation of reactive oxygen species gener-
ation, suppression of mitochondrial membrane potential
hyperpolarization, and amelioration of mitochondrial swelling
[92]. In another in vitro study, a 2-hour oxygen-glucose depri-
vation followed by a 24-hour reoxygenation in cultured hippo-
campal neurons showed that ginsenoside Rd administration
upregulates the endogenous antioxidant system including
glutathione and antioxidant enzymes, suppresses reactive oxygen
species production and lipid peroxidation, preserves mitochon-
drial membrane potential, and eventually, decreases apoptotic
death [70]. The treatment with ginsenoside Rd at doses of 10e
50 mg/kg decreases the infarct size and enhances neurological
function in both tMCAO-induced ischemic mice and rats [69,91].
Ginsenoside Rd also upregulates the endogenous antioxidant
system in ischemic penumbra, and decreases 8-hydroxy-deoxy-
guanosine (marker of DNA damage), hydroxyl radicals formation,
protein carbonyl, malondialdehyde, and 4-hydroxynonenal
(markers of lipid peroxidation), as well as advanced glycosyla-
tion end product levels [69]. It also decreases inflammation
through the downregulation of inducible nitric oxide synthase,
cyclooxygenase-2, and microglial activation [69].
A randomized, double-blind, placebo-controlled, Phase II
multicenter trial study on 199 patients suffering from ischemic
stroke showed that ginsenoside Rd infusion at doses of 10 and
20 mg/kg for 2 weeks significantly enhanced the National In-
stitutes of Health Stroke Scale when compared with the placebo
group [98]. However, ginsenoside Rd does not improve stroke
disability and daily activity in Barthel index and the modified
Rankin scales [98]. The authors of the study concluded that gin-
senoside Rd may be beneficial for ischemic patients [98]. Another
randomized, double-blind, placebo-controlled, multicenter trial
study on 390 patients suffering from acute ischemic stroke,
J Ginseng Res 2015;39:299e303302showed that a 2-week intravenous infusion of ginsenoside Rd
significantly enhanced the primary outcome and improved the
National Institutes of Health Stroke Scale and modified Rankin
scale at 90 days [71]. The study suggested that ginsenoside Rd can
have a promising neuroprotective role as adjuvant therapy in
acute ischemic patients.
4. Conclusion and recommendation
In conclusion, the available data suggest that the antiapoptotic,
antioxidant, and anti-inflammatory activities of ginsenoside Rd as
well as its ability to suppress calcium influx, may play a key role in
the neuroprotective action of this compound against ischemic
stroke. Ginsenoside Rd’s ability to upregulate GLT-1, phosphatidy-
linositol 3-kinase/AKT, and ERK1/2 signaling pathways, and to
inhibit poly(ADP-ribose) polymerase 1, glycogen synthase kinase-
3b, nuclear factor kappa B, apoptosis-inducing factor, cytochrome c
release, and caspase activation plays crucial role in prolonging
neuronal cell survival during an ischemic stroke and in the recovery
of cognitive function. However, owing to the lack of clinical studies
on ginsenoside Rd, it is difficult to make a clear decision. We
recommend that future studies on ginsenoside Rd should focus on
the following areas: (1) molecular mechanisms underlying the
beneficial role of ginsenoside Rd on ischemic stroke; (2) pharma-
cokinetic studies on ginsenoside Rd and finding methods to in-
crease its bioavailability using different delivery systems; (3)
pharmacodynamic studies on ginsenoside Rd and its possible
interactionwith well-known ischemic stroke drugs; and (5) clinical
studies to ascertain the best effective doses.
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